Nat Rev Cancer 2010, 10:293–301.PubMedCrossRef 39. Itamochi H: Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem 2010, 1:209–220.PubMedCrossRef 40. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643–646.PubMedCrossRef 41. Press JZ, De Luca A, Boyd N, et al.: Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8:17.PubMedCrossRef buy MRT67307 42. Helleday T: The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.

Mol Oncol 2011, 5:387–93.PubMedCrossRef 43. Fong PC, Boss DS, Yap TA, et al.: Inhibition of poly(ADP-ribose) polymerase 1 in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123–134.PubMedCrossRef 44. Fong PC, Yap TA, Boss DS, et al.: Poly(ADP)-ribose IWP-2 polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

J Clin Oncol 2010, 28:2512–2519.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions Dr. K wrote the manuscript, and Dr. E, Dr. U and Dr. N approved it. All authors read and approved the final manuscript.”
“Background Stem cells are Go6983 widely used in the treatment of malignant and nonmalignant diseases [1]. Advances in allogeneic hematopoietic stem cell transplantation (HSCT) have increased survival in hematologic diseases. Among those who survive the first 2 years, nearly 80% of allogeneic HSCT recipients are expected to become long-term survivors and by 2020 there may be up to half a million of these survivors worldwide [2, 3]. However, HSCT survivors are at risk of developing long-term complications. A fifth of HSCT survivors develop severe or life-threatening conditions [4]. Cardiac complications are frequently found life-threatening conditions. When cardiac dysfunction develops,

complete recovery of cardiac function occurs in only 42% of patients, despite pharmacological therapy [5]. Hence, new approaches for early cardiotoxicity detection need to be validated widely. Measurement of selleck kinase inhibitor cardiospecific biomarkers can be a valid diagnostic tool for early identification, assessment and monitoring of cardiotoxicity. This approach is minimally invasive, less expensive than echocardiography and easily repeated. Cardiac biomarkers are routinely evaluated only in patients before HSCT with increased cardiac risk [6, 7]. Future research should focus on the best timing for sampling, well-standardized methods for biomarkers determination and cut-off concentration that gives the best diagnostic accuracy in terms of sensitivity, specificity and predictive values.